MA27154A1 - Derives de quinazoline pour le traitement d'une croissance cellulaire anormale - Google Patents

Derives de quinazoline pour le traitement d'une croissance cellulaire anormale

Info

Publication number
MA27154A1
MA27154A1 MA27731A MA27731A MA27154A1 MA 27154 A1 MA27154 A1 MA 27154A1 MA 27731 A MA27731 A MA 27731A MA 27731 A MA27731 A MA 27731A MA 27154 A1 MA27154 A1 MA 27154A1
Authority
MA
Morocco
Prior art keywords
treatment
cell growth
abnormal cell
quinazoline derivatives
present
Prior art date
Application number
MA27731A
Other languages
English (en)
Inventor
John Charles Kath
Richard Damian Connell
James Dale Moyer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27154A1 publication Critical patent/MA27154A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 12 Décembre 2001 60/341,091 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de quinazoline pour le traitement d'une croissance cellulaire anormale La présente invention concerne des dérivés de quinazoline qui sont utiles dans le traitement d'une croissance cellulaire anormale, telle qu'un cancer, chez des mammifères. La présente invention concerne également une méthode d'utilisation de telles petites molécules dans le traitement d'une croissance anormale chez des mammifères, notamment chez l'homme, et des compositions pharmaceutiques contenant ces composés. La présente invention concerne en outre de petites molécules qui sont sélectives pour le récepteur erbB2 par rapport au récepteur erbB1, ledit inhibiteur de erbB2 ayant une gamme de sélectivités pour erbB2 par rapport au erbB1 de 50 à 1500.
MA27731A 2001-12-12 2004-06-08 Derives de quinazoline pour le traitement d'une croissance cellulaire anormale MA27154A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34109101P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
MA27154A1 true MA27154A1 (fr) 2005-01-03

Family

ID=23336198

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27731A MA27154A1 (fr) 2001-12-12 2004-06-08 Derives de quinazoline pour le traitement d'une croissance cellulaire anormale

Country Status (29)

Country Link
US (1) US20030171386A1 (fr)
EP (1) EP1465632A1 (fr)
JP (1) JP4181502B2 (fr)
KR (1) KR20040063948A (fr)
CN (1) CN1602195A (fr)
AP (1) AP2004003058A0 (fr)
AR (1) AR037771A1 (fr)
AU (1) AU2002339687A1 (fr)
BR (1) BR0214499A (fr)
CA (1) CA2469670A1 (fr)
DO (1) DOP2002000545A (fr)
EA (1) EA200400680A1 (fr)
EC (1) ECSP045146A (fr)
GT (1) GT200200273A (fr)
HR (1) HRP20040529A2 (fr)
HU (1) HUP0501069A2 (fr)
IL (1) IL161908A0 (fr)
IS (1) IS7233A (fr)
MA (1) MA27154A1 (fr)
MX (1) MXPA04004107A (fr)
NO (1) NO20042882L (fr)
OA (1) OA12734A (fr)
PA (1) PA8561301A1 (fr)
PE (1) PE20030760A1 (fr)
PL (1) PL373848A1 (fr)
TN (1) TNSN04111A1 (fr)
TW (1) TW200301121A (fr)
WO (1) WO2003049740A1 (fr)
ZA (1) ZA200404264B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP2280003B1 (fr) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Procédé pour la préparation de modulateurs de kinases de type récepteur
AU2003303045A1 (en) * 2002-12-18 2004-07-09 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
CA2509140A1 (fr) * 2002-12-19 2004-07-08 Pfizer Products Inc. Complexes de e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide et procedes de fabrication et d'utilisation correspondants
CA2536140A1 (fr) * 2003-08-18 2005-02-24 Pfizer Products Inc. Schema posologique pour des agents anticancereux inhibiteurs d'erbb2
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
EP2392565B1 (fr) 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1708712A1 (fr) * 2003-12-24 2006-10-11 Scios, Inc. Traitement de gliomas malignes avec des inhibiteurs de tgf-beta
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
NZ550796A (en) * 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
GB0417107D0 (en) * 2004-07-30 2004-09-01 Wellcome Trust The Genes II
CA2610491A1 (fr) * 2005-06-03 2006-12-07 Pfizer Products Inc. Derives bicycliques pour le traitement de croissance cellulaire anormale
EP1921070A1 (fr) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
RU2009126576A (ru) 2006-12-12 2011-01-20 Такеда Фармасьютикал Компани Лимитед (Jp) Конденсированное гетероциклическое соединение
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
CA2733153C (fr) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Heterocycles a substitution cyclohexyloxy, medicaments contenant ces composes, leur utilisation et procedes pour les preparer
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
WO2013033380A1 (fr) 2011-08-31 2013-03-07 Genentech, Inc. Marqueurs de diagnostic
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3806887A4 (fr) 2018-06-13 2022-04-06 California Institute of Technology Nanoparticules permettant de traverser la barrière hématoencéphalique et méthodes de traitement faisant appel à celle-ci
EP4100412A1 (fr) * 2020-02-03 2022-12-14 Boehringer Ingelheim International GmbH [1,3]diazino[5,4-d]pyrimidines utilisées en tant qu'inhibiteurs de her2
CN115052878B (zh) 2020-02-03 2024-07-09 勃林格殷格翰国际有限公司 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶
CN113429390B (zh) * 2020-03-23 2022-04-15 苏州恩华生物医药科技有限公司 喹唑啉衍生物及其应用
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP2003504363A (ja) * 1999-07-09 2003-02-04 グラクソ グループ リミテッド プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類
DZ3223A1 (fr) * 1999-10-19 2001-04-26 Merck & Co Inc Inhibiteurs de tyrosine kinases
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
HRP20040530A2 (en) * 2001-12-12 2004-10-31 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer

Also Published As

Publication number Publication date
BR0214499A (pt) 2005-05-10
CA2469670A1 (fr) 2003-06-19
PE20030760A1 (es) 2003-09-05
IS7233A (is) 2004-04-26
OA12734A (en) 2006-06-28
IL161908A0 (en) 2005-11-20
EP1465632A1 (fr) 2004-10-13
CN1602195A (zh) 2005-03-30
HRP20040529A2 (en) 2004-10-31
TNSN04111A1 (fr) 2006-06-01
PL373848A1 (en) 2005-09-19
PA8561301A1 (es) 2003-12-30
AP2004003058A0 (en) 2004-06-30
MXPA04004107A (es) 2004-07-23
AR037771A1 (es) 2004-12-01
TW200301121A (en) 2003-07-01
US20030171386A1 (en) 2003-09-11
GT200200273A (es) 2003-10-03
JP2005527486A (ja) 2005-09-15
NO20042882L (no) 2004-07-07
EA200400680A1 (ru) 2005-06-30
ECSP045146A (es) 2004-07-23
ZA200404264B (en) 2005-08-31
HUP0501069A2 (en) 2006-06-28
DOP2002000545A (es) 2003-06-16
JP4181502B2 (ja) 2008-11-19
KR20040063948A (ko) 2004-07-14
AU2002339687A1 (en) 2003-06-23
WO2003049740A1 (fr) 2003-06-19

Similar Documents

Publication Publication Date Title
MA27154A1 (fr) Derives de quinazoline pour le traitement d'une croissance cellulaire anormale
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA27142A1 (fr) Derives de piperazine a activite antagoniste des recepteurs ccr1
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
WO2002046170A8 (fr) Derives d'anilinopyrimidine utilises comme inhibiteurs du chemin de la kinase de n terminal (jnk) et compositions et techniques associees
MA27174A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4.
TNSN06038A1 (fr) Derives d'indazole 3,5-disubstitues, compositions pharmaceutiques, et methodes de mediation ou d'inhibition de la proliferation cellulaire
MA31466B1 (fr) Derives de benzimidazole
DK0888111T3 (da) Modified-release-dosispræparat med multiple enheder
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
MA26997A1 (fr) Derives de 3-(4-amidopyrrole-2-ylmethylidene)-2-indolinone utilisables comme inhibiteurs de proteine-kinases
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
CA2312545A1 (fr) Composition pharmaceutique solide thermoformable a liberation controlee
AU2003228674A1 (en) Muscarinic antagonists
MA29797B1 (fr) DERIVES DE LA PYRROLOPYRIMIDINE INHIBITEURS DE LA Syk
AU2003281200A1 (en) Immunopotentiating compositions
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
WO2000002542A3 (fr) Agent a effet antidepressif
AU3451797A (en) Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
MA27190A1 (fr) Derives de tropane servant de modulateurs de ccr5
MA26965A1 (fr) Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.